Allogene Therapeutics News and Activities

Presence

Allogene Therapeutics develops cell therapies for cancer treatment. Its main products and services include research, clinical development, and manufacturing support for hospitals, doctors, and patients in oncology care.

Allogene Therapeutics products and services overview:

Cell therapies
Cancer treatments
Clinical development
Drug research
Biotech manufacturing

Revenue: ~$39 million

Employees: 230

Headquarters: South San Francisco, United States (USA)

Allogene Therapeutics is one of the...

Allogene Therapeutics is a company listed under the stock ticker ALLO (US).

Executives

View the org chart displaying its 25 main executives

Most searched biographies at Allogene Therapeutics

Popular executive movements at Allogene Therapeutics

Zachary Roberts who is Executive Vice President, Research & Development and Chief Medical Officer, will become Chief Executive Officer and Interim Chief Medical Officer on Jul. 1, 2026 (posted on May 30 2026).
David Chang, President and Chief Executive Officer, will leave the company on Jun. 30, 2026 (posted on May 30 2026).
Sri Ghatta, Senior Director, Clinical Development, has left the company (posted on April 9 2026).

Create your alert
to follow the executive moves at Allogene Therapeutics.